secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001937653-24-000049
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks reports 9M 2024 net loss $99.2M; cash $374.9M; completes $30M buyback; advances pipeline
--------------------------------------------------------------------------------

- Net loss $99.2M for nine months ended Sep 30, 2024 vs $104.2M loss prior year; revenue $45.3M vs $59.1M.
- Cash resources $374.9M (cash, equivalents, marketable securities) as of Sep 30, 2024; projected runway into 2H 2027 including milestones.
- Completed initial $30M share repurchase: 2,545,402 shares at avg $11.79 as of Oct 31, 2024.
- First patient dosed in Phase 1 trial of ZW171 for MSLN-expressing cancers; preclinical data presented for ZW220 and ZW251.
- Director Hollings C. Renton resigns from board effective Dec 10, 2024; not due to disagreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000193765324000049/0001937653-24-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000193765324000049/zyme-20241031.htm
  HTML page:      https://secwatch.observer/filing/0001937653-24-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer